India covid-19 vaccine India

Intranasal covid-19 vaccine safe, immunogenic: Bharat Biotech

Reading now: 956
www.livemint.com

Bharat Biotech International Ltd. on Monday said its intra-nasal covid-19 vaccine, BBV154, is safe, well-tolerated, and immunogenic in subjects studied during phase 3 clinical trials for primary dose and a heterologous booster dose.

The company said data from phase 3 trials have been submitted for approval to national regulatory authorities. BBV154 is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein.

The vaccine candidate was evaluated earlier in phase I and II clinical trials with successful results. BBV154 has been specifically formulated to allow intra-nasal delivery.

In addition, the nasal delivery system has been designed and developed to be cost-effective in low and middle-income countries.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA